Closed Loop Insulin Delivery 2026 — PatSnap Eureka
Closed Loop Insulin Delivery: Technology Landscape 2026
From clinical proof-of-concept in 2009 to commercial deployment across North America and Europe, closed loop insulin delivery has undergone a decisive transformation. This landscape maps the IP, algorithms, hardware, and emerging directions shaping the field today.
Three Subsystems, One Convergent Platform
Closed loop insulin delivery (CLID)—commonly termed the artificial pancreas—unifies a continuous glucose sensor, a real-time control algorithm, and an insulin infusion device into a single autonomous system. As documented by the University of Cambridge, the dominant validated configuration uses subcutaneous CGM coupled to a continuous subcutaneous insulin infusion (CSII) pump under software-based control, with algorithm cycles updating every 15 minutes.
The technology has completed a decisive transition from controlled clinical settings into real-world commercial deployment, with multiple hybrid closed-loop (HCL) systems now approved and in active use across North America, Europe, and beyond. Commercial IP is concentrated in four US-headquartered companies — Dexcom, Abbott Diabetes Care, Medtronic MiniMed, and Bigfoot Biomedical — all with European Patent extensions. Research on life sciences innovation intelligence via PatSnap reveals that academic contributions from the Asia-Pacific region (Harbin Institute of Technology, Tsinghua University) appear in the literature subset, indicating pre-commercial activity.
The World Health Organization estimates over 422 million people worldwide have diabetes, underscoring the scale of unmet need that closed loop systems address. Understanding the freedom-to-operate landscape requires comprehensive IP analytics across CGM integration, IOB calculation methods, and safeguard controller architectures.
From Inpatient Feasibility to Commercial Scale: 2009–2024
The dataset spans 15 years of publication activity, enabling a clear maturity trajectory from controlled clinical settings to real-world platform deployment.
This landscape is derived from patent and literature records retrieved across targeted searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full industry.
Key Metrics Across the Closed Loop Insulin Delivery Landscape
Quantitative signals extracted from patent filings, clinical studies, and real-world datasets in this landscape analysis.
Commercial Patent Assignees — Dataset Distribution
All 4 commercial patent holders are US-domiciled with European Patent extensions. Dexcom and Bigfoot Biomedical each hold 2 records; Medtronic MiniMed and Abbott each hold 1.
Open-Source AID — Time-in-Range Performance
Stanford prospective study (558 Loop users) showed TIR improved from 67% to 73% over 6 months. Pig model comparison found AndroidAPS achieved 58% vs. 35% for Loop under full closed-loop.
Four Innovation Clusters Shaping the Artificial Pancreas
Patent and literature analysis reveals four structurally distinct clusters of innovation, from commercially validated algorithms to open-source platforms and biochemical delivery.
Model Predictive Control (MPC)
MPC is the dominant algorithmic paradigm in commercially validated hybrid closed-loop systems. It uses a mathematical model of glucose-insulin dynamics to predict future glucose trajectories and compute insulin doses minimising deviations from target range while avoiding hypoglycemia. Cambridge's MPC algorithm — updating pump basal rates every 15 minutes from CGM inputs — was validated across populations from pregnant women to adolescents. Gaussian Process-MPC extensions, tested using the UVa/Padova FDA-accepted metabolic model, handle circadian insulin sensitivity variation.
Abbott Diabetes Care EP · Medtronic MiniMed EPPID and Advanced Classical Control
Proportional-Integral-Derivative (PID) control, enhanced with insulin-on-board (IOB) feedback and anti-windup strategies, represents an earlier but still active control lineage. The University of California Santa Barbara designed a fully implantable artificial pancreas using a PID controller tuned for intraperitoneal delivery, achieving 78% time in the 80–140 mg/dL range. Gain-scheduled observers and sliding mode control variants extend classical PID toward finite-time stability guarantees. The FDA has accepted the UVa/Padova simulator as a validation tool for in-silico PID testing.
Harbin Institute · UC Santa Barbara · Prince Sattam UniversityOpen-Source and DIY Automated Insulin Delivery
OpenAPS, Loop, and AndroidAPS operate outside regulated commercial channels using community-developed algorithms. The OpenAPS Data Commons contains over 46,070 days of data and 10 million CGM data points — the largest freely available diabetes dataset. A 2021 Stanford prospective study of 558 Loop users (ages 1–71) reported mean time-in-range improving from 67% to 73% over 6 months. With 897+ survey respondents from 35 countries self-reporting use of DIY AID systems, this represents a structural competitive threat and opportunity for commercial developers. See how innovators use PatSnap to monitor open-source algorithm developments.
Stanford University · OpenAPS Data CommonsHardware Integration and Sensing Architectures
IP filings from Dexcom, Bigfoot Biomedical, and Medtronic MiniMed focus on system-level integration of CGM, controller, and delivery device as a unified hardware platform. Dexcom's EP patents describe manual-to-fully-automated integration modes. Bigfoot Biomedical's IOB-tracking patent introduces a relative insulin-on-board metric — subtracting automated IOB from reference IOB — to refine bolus dosing algorithmically. A distinct biochemical cluster (University of Texas Austin, Nagoya University) uses glucose-responsive hydrogels and nanomaterials to bypass electronic control entirely via phenylboronic acid or glucose oxidase chemistry.
Dexcom EP 2024 · Bigfoot EP 2023 · Nanomaterial systemsClinical Populations and Use Cases Across the Dataset
Closed loop insulin delivery evidence spans pediatric T1D, pregnancy, inpatient settings, and emerging type 2 diabetes applications.
Type 1 Diabetes — Pediatric Populations
The most densely represented application in this dataset. Studies span neonates (ages 2–5 years, Omnipod 5 trial, Stanford 2022) through adolescents. Very young children (2.0–5.9 years) showed a 10.9% TIR increase and no severe hypoglycemia in the Omnipod 5 single-arm multicenter trial. A one-year real-world study from the University of Messina confirmed "the supremacy of hybrid closed-loop systems" over predictive-suspend and non-automated pumps in pediatric populations.
Type 1 Diabetes in Pregnancy
A specialized but clinically critical domain. Cambridge studies (2011) validated MPC-based closed-loop in pregnant women at 12–32 weeks gestation, demonstrating reduced hypoglycemia. Harvard's Zone-MPC algorithm (2022) was specifically tuned to the tighter pregnancy glucose target of 63–140 mg/dL and changing insulin requirements with advancing gestation. King's College Hospital showed safety of 24-hour closed-loop in well-controlled pregnant women.
Five Frontiers Defining the Next Generation of Closed Loop Delivery
Based on the most recent filings and publications in this dataset (2022–2024), five emerging directions are shaping R&D and IP strategy.
Innovation Maturity by System Type
Hybrid closed-loop dominates the commercial and clinical evidence base; fully closed-loop and biochemical systems remain in research or pre-commercial stages.
Multiple records point toward eliminating user-initiated meal boluses. The Stanford pig model study (2021) and the CREATE trial (University of Waikato) explicitly test full closed-loop without carbohydrate entries. Cambridge's 2022 review identifies this as "the primary future challenge."
A 2022 systematic review evaluates dual insulin-and-pramlintide artificial pancreas systems, identifying 4 crossover studies demonstrating improved postprandial control. Bihormonal (insulin + glucagon) systems target complete physiological mimicry.
Dexcom's April 2024 EP patent describes a modular architecture supporting manual, semi-automated, and fully automated modes — a platform strategy serving multiple clinical personas and regulatory pathways simultaneously.
What the IP Landscape Means for R&D Teams and New Entrants
Commercial IP is highly concentrated in four US-domiciled companies — Dexcom, Abbott, Medtronic MiniMed, and Bigfoot Biomedical — with EP extensions, creating significant freedom-to-operate constraints for new entrants in regulated markets. New market entrants should conduct thorough FTO analysis particularly around CGM integration, IOB calculation methods, and safeguard controller architectures. Use PatSnap's IP analytics platform to map these constraints systematically.
The open-source AID movement represents a structural competitive threat and opportunity: with 897+ survey respondents from 35 countries self-reporting use of DIY AID systems (OpenAPS, Loop, AndroidAPS) and large real-world datasets already accumulated, commercial developers can either incorporate community-derived algorithm insights or risk commoditization of their software differentiation.
Pediatric and pregnancy populations are underserved yet high-value niches. The preponderance of clinical evidence concerns adult T1D. Specialized regulatory pathways for children under 6 years and pregnant women remain less crowded, with Cambridge and Stanford dominating early evidence — representing accessible beachhead positions for differentiated product claims. The European Medicines Agency has specific pediatric investigation plan requirements that shape IP strategy in this space. For life sciences IP strategy, PatSnap's life sciences solution provides dedicated tools for regulatory pathway mapping.
Nanomaterial and biochemical closed-loop systems are pre-commercial but IP-foundational. Glucose-responsive hydrogel and nanoparticle systems have no commercial products in this dataset but several active research programs. Early patent prosecution in this domain — particularly around phenylboronic acid release kinetics and biocompatible encapsulation — could yield foundational blocking positions for a fully implantable, electronics-free artificial pancreas generation. Explore the PatSnap Open API for programmatic access to nanomaterial patent data.
Closed Loop Insulin Delivery — key questions answered
Closed loop insulin delivery systems unify three functional subsystems: a continuous glucose sensor (interstitial or intraperitoneal), a control algorithm (model predictive control, PID-based, or machine learning-augmented), and an insulin infusion device (subcutaneous pump or tubeless patch). The dominant configuration uses subcutaneous CGM coupled to a continuous subcutaneous insulin infusion pump under software-based algorithmic control, with algorithm cycles typically updating insulin delivery every 15 minutes.
Hybrid closed-loop (HCL) systems use algorithm-directed basal modulation with user-announced meal boluses and represent the dominant commercial paradigm. Advanced hybrid closed-loop (AHCL) systems add automated bolus correction in addition to basal modulation. Fully closed-loop systems require no meal announcements and are emerging in research settings.
Among the patent records in this dataset, four distinct commercial entities dominate: Dexcom (2 EP patents), Bigfoot Biomedical (2 US/EP patents), Medtronic MiniMed (1 EP patent), and Abbott Diabetes Care (1 EP patent). All four are US-headquartered companies with patent protection extending into the European Patent jurisdiction.
A 2021 Stanford prospective study of 558 Loop users (ages 1–71) reported mean time-in-range improving from 67% to 73% over 6 months. The OpenAPS Data Commons dataset contains over 46,070 days of data and 10 million CGM data points. A Stanford pig model study (2021) compared AndroidAPS vs. Loop under full closed-loop conditions without meal announcements, finding AndroidAPS achieved 58% TIR vs. 35% for Loop.
Based on the most recent filings and publications (2022–2024), five emerging directions are identified: (1) fully closed-loop operation without meal announcements, (2) dual-hormone and multi-agent delivery combining insulin with glucagon or pramlintide, (3) platform convergence and interoperability across manual, semi-automated, and fully automated modes, (4) biochemical/nanomaterial glucose-responsive delivery using hydrogels and nanoparticles, and (5) cost-effectiveness and health-economic validation for payer access.
Pediatric populations are the most densely represented application in this dataset. Very young children (2.0–5.9 years) showed a 10.9% TIR increase and no severe hypoglycemia in the Omnipod 5 single-arm multicenter trial. For pregnancy, Cambridge studies (2011) validated MPC-based closed-loop in pregnant women at 12–32 weeks gestation, and Harvard's Zone-MPC algorithm (2022) was specifically tuned to the tighter pregnancy glucose target of 63–140 mg/dL.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka Your QuestionMap the Full Closed Loop Insulin Delivery Patent Landscape
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and identify IP whitespace before competitors do.
References
- Closed-loop insulin delivery: update on the state of the field and emerging technologies — University of Cambridge / Wellcome Trust-MRC, 2022
- Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions — St Vincent's Hospital / University of Sydney, 2022
- Closed-loop insulin delivery for treatment of type 1 diabetes — University of Cambridge, 2011
- New closed-loop insulin systems — University of Cambridge / Wellcome Trust-MRC, 2021
- Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model — Abbott Diabetes Care Inc., EP, 2019
- Insulin delivery controller — Bigfoot Biomedical Inc., US, 2018
- Insulin delivery systems and methods — Bigfoot Biomedical Inc., EP, 2023
- Integrated insulin delivery system with continuous glucose sensor — Dexcom Inc., EP, 2023
- Integrated insulin delivery system with continuous glucose sensor — Dexcom Inc., EP, 2024
- Safeguard measures for a closed-loop insulin infusion system — Medtronic MiniMed Inc., EP, 2023
- Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes — R&B Medical Group, 2022
- One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology — University of Virginia Center for Diabetes Technology, 2021
- A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System — Stanford University, 2021
- Large-Scale Data Analysis for Glucose Variability Outcomes with Open-Source Automated Insulin Delivery Systems — OpenAPS, 2022
- Full closed loop open-source algorithm performance comparison in pigs with diabetes — Stanford Diabetes Research Center, 2021
- Zone-MPC Automated Insulin Delivery Algorithm Tuned for Pregnancy Complicated by Type 1 Diabetes — Harvard University, 2022
- Safety and Efficacy of 24-h Closed-Loop Insulin Delivery in Well-Controlled Pregnant Women With Type 1 Diabetes — King's College Hospital, 2011
- Fully closed-loop insulin delivery in inpatients receiving nutritional support — Bern University Hospital / University of Cambridge, 2019
- Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review — Spanish Network of HTA Agencies, 2022
- An Improved PID Algorithm Based on Insulin-on-Board Estimate for Blood Glucose Control — Harbin Institute of Technology, 2015
- Design and Evaluation of a Robust PID Controller for a Fully Implantable Artificial Pancreas — University of California Santa Barbara, 2015
- Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children — Stanford University, 2022
- Recent advances in glucose-responsive insulin delivery systems: novel hydrogels and future applications — University of Texas at Austin, 2022
- The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden — Medtronic Denmark, 2021
- World Health Organization — Diabetes fact sheet and global prevalence estimates
- U.S. Food and Drug Administration — Artificial Pancreas Device Systems guidance and approvals
- European Medicines Agency — Pediatric investigation plans and regulatory guidance for insulin delivery devices
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.